Sunday 18 October 2026
Export IGC’s income statement to Excel — free account
IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024. In the quarter to June 2026, revenue fell 19.7%, EPS fell 100.0%, free cash flow fell 103.3% and total debt rose 713.5%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
0.25
0.00
0.00%
Follow IGC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
24.60 | 21.89 | — | 34.35 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(20.07) | (20.87) | — | (27.94) | |
P/B ratio |
4.42 | 4.17 | — | 4.70 | |
Price to Tangible BV |
43.34 | 29.92 | — | 11.82 | |
EV/Sales |
25.27 | 22.47 | — | 33.57 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(5.21) | (5.55) | — | (7.71) | |
EV/FCF |
(4.89) | (5.56) | — | (7.68) | |
Quick Ratio |
0.13 | 0.09 | 0.44 | 0.77 | |
Current Ratio |
0.39 | 0.40 | 0.83 | 1.32 | |
Net Debt/EBITDA |
(0.27) | (0.28) | 0.00 | 0.34 | |
Debt/Assets |
11.39% | 9.98% | 3.20% | 1.35% | |
Debt/Equity |
0.18 | 0.15 | 0.04 | 0.02 | |
Asset Turnover |
0.13 | 0.13 | 0.00 | 0.11 | |
Operating CF/Net income |
0.46 | 0.51 | — | 0.75 | |
Capex/Depreciation |
(7.55) | (0.02) | — | 5.91 | |
Research and Development Expense of Revenue |
524.53% | 401.26% | — | 831.41% | |
Selling, General and Administrative Expense of Revenue |
544.15% | 391.48% | — | 738.22% | |
Intangible Assets out of Total Assets |
0.58 | 0.57 | 0.53 | 0.50 | |
Share Based Compensation of Revenue |
281.89% | 318.30% | — | 143.98% | |
Graham Net Nets |
(0.08) | (0.08) | — | 0.01 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(33.33%) | (28.85%) | — | (17.86%) | |
Free Cash Flow Yield |
(20.99%) | (18.47%) | — | (12.73%) | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.01) | (0.01) | — | (0.01) | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(0.02) | (0.01) | — | (0.02) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Shareholders Equity per Share |
0.06 | 0.06 | 0.00 | 0.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.06 | 0.06 | 0.00 | 0.09 | |
Free Cash Flow |
(1.77) | (1.22) | — | (1.57) | |
Working Capital |
(1.95) | (1.73) | (0.37) | 0.49 | |
Capital Expenditures |
(0.42) | 0.00 | — | (0.21) | |
Net Current Asset Value |
(2.10) | (1.92) | (0.50) | 0.35 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
1.60 | 0.00 | — | 1.08 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.07 | 0.04 | 0.03 | 0.04 | |
Average Payables |
1.28 | 1.07 | 0.92 | 0.70 | |
Average Inventory |
0.99 | 1.00 | 1.04 | 1.08 | |
Average Assets |
8.72 | 8.97 | 9.40 | 10.06 | |
Average Common Equity |
6.11 | 6.23 | 6.84 | 7.73 |
Columns are period end dates · fundamentals updated 5 Oct 2026